Mal-PEG4-NPV-PABC-DMEDA-tofacitinib

Overview

Mal-PEG4-NPV-PABC-DMEDA -tofacitinib is a conjugate of a toxin and a linker, consisting of the JAK inhibitor Tofacitinib ( HY-40354 ) and the linker Mal-PEG4-NPV-PABC-DMEDA ( HY-182977 ). Mal-PEG4-NPV-PABC-DMEDA -tofacitinib can be used for the synthesis of ADC molecules.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Signaling Pathways > Antibody-Drug Conjugate/ADC Related | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Drug-Linker Conjugates for ADC | Products > Signaling Pathways > JAK

Product Information

• Catalog No.: HY-182972
• CAS No.: 3110422-32-4
• Molecular Formula: C58H80N14O15
• Molecular Weight: 1213.34
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source